Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Technetium-99m radiolabeled heparin
- Development stage
- Phase 2
- Lead developer
- NexEos Bio
- Modality
- Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Oral
01
Overview
NDX-3315 is an investigational, non-invasive oral radiopharmaceutical imaging agent designed to assist in the detection, diagnosis, monitoring, and treatment management of eosinophilic esophagitis (EoE). It consists of technetium-99m-labeled heparin and is intended to improve upon current diagnostic standards by providing a reliable method for identifying and localizing inflammation in the esophagus. The agent enhances single-photon emission-computed tomography (SPECT) imaging. Developed by NexEos Diagnostics (also referred to as NexEos Bio), it has received orphan drug designation for EoE and is currently being evaluated in phase 2 clinical trials for this indication[1][2][3][4][5].
- Other names
- technetium-99m radiolabeled heparintechnetium99m radiolabeled heparintechnetium 99m radiolabeled heparin
02
Targets
PRG2 (Major basic protein 1)
Beyond the preview
Go deeper on Technetium-99m radiolabeled heparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Technetium-99m radiolabeled heparin.